Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Keryx Biopharmaceuticals Clear all
Completed Phase 3 Interventional Results available

A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis

NCT01554982
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Renal Failure, Hyperphosphatemia, ESRD
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
33
States / cities
Los Angeles, California • Aurora, Colorado • Westminster, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 6, 2026, 10:12 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

NCT02661295
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions
Ferric Citrate
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 6, 2026, 10:12 AM EDT
Active, not recruiting Phase 4 Interventional

Ferric Citrate in ESRD Pilot Project

NCT03055598
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Ferric Citrate
Drug
Lead sponsor
Sreedhar Mandayam
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

NCT01736397
View directory record Official record
Conditions
Iron Deficiency, Iron Deficiency Anemia
Interventions
Ferric Citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Tempe, Arizona • La Mesa, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

NCT02268994
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
ferric citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Phoenix, Arizona • Tempe, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT02492620
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions
Ferric Citrate
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT00873457
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
perifosine
Drug
Lead sponsor
Daphne Friedman
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

NCT01191255
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Failure
Interventions
ferric citrate, ca acetate, sevelamer carbonate, placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
52
States / cities
Tempe, Arizona • Los Angeles, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

NCT03079869
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Ferric Citrate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

NCT01074125
View directory record Official record
Conditions
Hyperphosphatemia, End-Stage Renal Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
15
States / cities
Westminster, Colorado • Pembroke Pines, Florida • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

NCT00590954
View directory record Official record
Conditions
Malignant Gliomas, CNS, Brain Cancer, Cancer
Interventions
Perifosine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

NCT00648167
View directory record Official record
Conditions
Hyperphosphatemia, End-stage Renal Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Effect of Sulodexide in Early Diabetic Nephropathy

NCT00130208
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

NCT03236246
View directory record Official record
Conditions
Chronic Kidney Diseases, Iron Deficiency Anemia
Interventions
KRX-0502
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • Chula Vista, California • El Centro, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 6, 2026, 10:12 AM EDT
Terminated Phase 4 Interventional

Effect of Sulodexide in Overt Diabetic Nephropathy

NCT00130312
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 6, 2026, 10:12 AM EDT
Suspended Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727
View directory record Official record
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
6 Years to 16 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 6, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

NCT00431054
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Perifosine, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 6, 2026, 10:12 AM EDT